Global Cord Blood Corp. (CORBF)
OTOTC · Common · CUSIP G39342103
Last Price•••.••
Current Yield•.••%
Yield to Call•.••%
Yield to Worst•.••%
Free registration unlocks the quote, yield calculations, price chart and full fundamentals for CORBF and every other security on QuantumOnline.
🔒
Price chart and 15 days of daily prices
Candlestick chart with moving averages, Bollinger bands and MACD. Register free to view.

Security Profile

Security Type
Common Stock
CUSIP
G39342103 (prev. 698659109 )
Market Cap
Large Cap
Previous Symbol
CO (changed 6/15/2023)
Previous Name
China Cord Blood Corp.
Business: Global Cord Blood Corporation is a life sciences enterprise dedicated to the storage of umbilical cord blood stem cells. Leveraging the rapid developments in life sciences research and the increasing popularity and continuous new developments of clinical applications using stem cells, the Company endeavors to provide umbilical cord blood storage services for parents to save cord blood stem cells on behalf of their children, in China and the Asia Pacific regions, to safeguard the lives and health of their newborns. Global Cord Blood Corporation is the first cord blood banking operator approved by the Ministry of Health, the People's Republic of China, to engage in the cord blood banking business. Global Cord Blood Corporation provides exclusive cord blood storage services in the Beijing Municipality, the Guangdong Province and the Zhejiang Province.
Notes: September 22, 2022 -- the Grand Court of the Cayman Islands issued an order appointing Joint Provisional Liquidators (the “JPLs”) over the Company. Since their appointment, the JPLs have publicly disclosed that, as a result of certain improper activity before and after their appointment, the operating business and assets of the Company’s subsidiaries in the People’s Republic of China were transferred away from the Company. The JPLs are taking steps to restore the Company’s position with respect to those operating businesses and assets, but as of the date hereof the situation remains unresolved. As a result, NYSE Regulation reached the decision that the Company is no longer suitable for listing. The NYSE may consider any event or condition which may exist or occur that makes further dealings or listing on the Exchange inadvisable or unwarranted in the opinion of the Exchange.

Company Contact

CEO
ZHENG Ting
CFO
CHEN Bing Chuen
Investor Relations
William Zima, ICR Inc. · 646-405-5185 · william.zima@icrinc.com
General Email
ir@chinacordbloodcorp.com
SEC EDGAR Filings
View filings »